Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study

Table 3 Univariate analysis of prognostic variables in patients with EGFR mutations receiving EGFR-TKIs

Characteristic	HR	95% CI	P value
Sex (female vs. male)	0.930	0.824–1.094	0.237
Age (≤ 65 years vs. > 65 years)	0.832	0.729–0.949	0.006
Pathological type (adenocarcinoma vs. others NSCLC)	0.794	0.649–0.972	0.025
ECOG PS (2 vs. 0–1)	24.454	20.244–29.539	< 0.001
Smoking history (yes vs. no)	1.001	0.882–1.136	0.986
EGFR-mutation subtype (Exon 19 deletion vs. L858R)	0.870	0.771–0.982	0.025
Brain metastasis (yes vs. no)	1.244	1.099–1.409	0.001
Bone metastasis (yes vs. no)	1.333	1.180–1.506	< 0.001
Operation History (yes vs. no)	0.621	0.528–0.731	< 0.001
Radiotherapy (yes vs. no)	0.908	0.802–1.028	0.129
Chemotherapy (yes vs. no)	0.802	0.704–0.913	0.001
Baseline anemia (yes vs. no)	1.256	1.098–1.436	0.001

EGFR Epidermal growth factor receptor, ECOG PS Eastern Cooperative Oncology Group Performance status, NSCLC Non-small cell lung cancer, TKI Tyrosine kinase inhibitor

ISSN: 1471-2466